Enlicitide and PCSK9 Inhibition for Long-Term LDL Cholesterol Reduction
|
Reviewed & Translated by Dat Tien Nguyen, B.A, ScM.
|
Posted on March 13th, 2026
|
Effective control of low-density lipoprotein (LDL) cholesterol is central to preventing atherosclerosis and its downstream cardiovascular complications. PCSK9 plays a key role in LDL metabolism by binding to LDL receptors and promoting their degradation within hepatocytes, thereby limiting LDL clearance from the circulation. Enlicitide is a novel agent that disrupts the interaction between PCSK9 and the LDL receptor, preserving receptor availability on hepatocytes and enhancing removal of LDL cholesterol from the bloodstream. A recent study published in the New England Journal of Medicine evaluated the efficacy of enlicitide in lowering LDL cholesterol levels.
Funding Source(s): Merck Sharp & Dohme
The phase 3 clinical trial enrolled 2,909 participants with a mean age of 62.8 years. More than half of the cohort (58.3%) had a history of major atherosclerotic cardiovascular events, including myocardial infarction or ischemic stroke. At baseline, the average LDL cholesterol level was 96.1 mg/dL, and mean apolipoprotein B concentration was 91.2 mg/dL. Nearly all participants (96.6%) were receiving statin therapy, and 25.8% were also treated with a cholesterol-absorption inhibitor.
Participants were randomly assigned to receive either placebo or enlicitide at a daily oral dose of 20 mg. After 52 weeks of therapy, treatment with enlicitide resulted in an approximately 50% reduction in LDL cholesterol from baseline, with measurable effects observed as early as four weeks after initiation. Apolipoprotein B levels showed a parallel and significant decline. Importantly, long-term treatment was not associated with a meaningful increase in adverse events compared with placebo. Future studies should directly compare enlicitide with other PCSK9-targeted therapies and assess whether LDL lowering with this agent translates into reduced rates of atherosclerotic cardiovascular events.
Funding Source(s): Merck Sharp & Dohme
The phase 3 clinical trial enrolled 2,909 participants with a mean age of 62.8 years. More than half of the cohort (58.3%) had a history of major atherosclerotic cardiovascular events, including myocardial infarction or ischemic stroke. At baseline, the average LDL cholesterol level was 96.1 mg/dL, and mean apolipoprotein B concentration was 91.2 mg/dL. Nearly all participants (96.6%) were receiving statin therapy, and 25.8% were also treated with a cholesterol-absorption inhibitor.
Participants were randomly assigned to receive either placebo or enlicitide at a daily oral dose of 20 mg. After 52 weeks of therapy, treatment with enlicitide resulted in an approximately 50% reduction in LDL cholesterol from baseline, with measurable effects observed as early as four weeks after initiation. Apolipoprotein B levels showed a parallel and significant decline. Importantly, long-term treatment was not associated with a meaningful increase in adverse events compared with placebo. Future studies should directly compare enlicitide with other PCSK9-targeted therapies and assess whether LDL lowering with this agent translates into reduced rates of atherosclerotic cardiovascular events.